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Essay
T
here were an estimated 536,000 
maternal deaths in the world in 
2005, of which 533,000 (99%) 
occurred in developing countries [1]. 
Maternal and perinatal conditions are a 
major contributor to the global burden 
of disease, yet the pipeline of new 
drugs specifically for maternal health is 
alarmingly small [2]. Only 17 drugs are 
under active development for maternal 
health indications—less than 3% of the 
pipeline in cardiovascular health. Since 
the disaster of thalidomide 50 years 
ago, the medical profession has been 
rightfully very cautious about giving 
newly developed drugs to pregnant 
women, for fear that they might 
damage the unborn baby. Particular 
caution has been exercised in the first 
trimester to avoid teratogenicity during 
organogenesis. 
A Dangerous “Catch-22”
The result has been that newly 
introduced medicines often carry a 
prescribing caveat that they should 
not be used in pregnancy. There 
may have been no worrying results 
from reproductive toxicology testing 
to warrant this caution—simply 
insufficient clinical information in 
pregnancy. But for a new drug, there 
is never sufficient clinical information 
in pregnancy. Pregnant women with 
potentially fatal illnesses may be 
treated with inferior drugs to avoid a 
hypothetical risk to the unborn child 
(and the consequent liability). 
Realising that this was a 
dangerous “Catch-22”—medicines 
not recommended therefore not 
prescribed—not prescribed therefore 
no information—regulatory authorities 
in developed countries have begun to 
encourage pharmaceutical companies 
to gather information on the use of 
new drugs in pregnancy. In tropical 
countries, where infectious diseases 
account for half of all deaths, and 
99% of maternal deaths occur, the 
treatment of infections in pregnancy 
is particularly problematic. There are 
few or no studies in pregnancy on most 
drugs used for the treatment of tropical 
infections, and so few or no evidence-
based recommendations. 
Malaria in Pregnancy
Malaria, the most important parasitic 
infection of humans, illustrates this 
problem well. Malaria infects about 
5% of the world’s population at any 
time, and is a particular problem 
in pregnancy. There is a renewed 
international interest in the infection, 
and malaria in pregnancy is rightly 
considered a priority area. Malaria 
in pregnancy reduces birth weight 
(and thereby infant survival). In low-
transmission areas there is an increased 
risk of severe falciparum malaria and 
consequent death of both mother and 
foetus [3]. The health community has 
finally realised that even if the mother 
is asymptomatic, the presence of 
malaria parasites in the blood is always 
harmful to the foetus and must be 
treated promptly and effectively. 
But treated with what? There 
have been remarkably few studies 
of antimalarial drugs in pregnancy. 
Of over 500 antimalarial drug 
trials conducted between 1966 and 
December 2006, only 31 evaluated 
antimalarial treatments (including 
intermittent preventive treatments) 
specifically in pregnant women (and 
14 of these were from a single centre) 
[4]. Only primaquine and tetracyclines 
are considered contraindicated in 
pregnancy, although the evidence 
base for the safety of widely used 
antimalarials such as amodiaquine 
is weak [5], and recommended dose 
regimens for pregnant women are all 
derived from studies in non-pregnant 
adults. 
Drug regimens should be 
recommended on the basis of 
pharmacokinetic and pharmacodynamic 
information in the target population. 
Where blood or plasma concentrations 
of the antimalarial drugs have 
been measured in late pregnancy, 
they have usually been found to 
be reduced [6,7]. For artemether, 
dihydroartemisinin, atovaquone, 
proguanil, and lumefantrine, the 
reductions have been substantial, 
and likely to have contributed to 
poor therapeutic responses, yet there 
have been no studies of higher dose 
regimens in pregnancy. In recent 
years, sulfadoxine–pyrimethamine (SP) 
replaced chloroquine as the most widely 
used antimalarial drug in pregnancy. 
However, the pharmacokinetic 
properties of sulfadoxine and 
pyrimethamine in pregnancy have 
only just been reported, years after 
the policy recommendations and 
widespread deployment of SP first as 
a treatment and later as intermittent 
preventive treatment in pregnancy. 
Blood concentrations of sulfadoxine 
were found to be 40% lower during 
pregnancy compared with after 
pregnancy [8], suggesting that the dose 
of SP in pregnancy may have been too 
low.
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Safety of Artemisinin Derivatives 
in Pregnancy
The safety of the artemisinin derivatives 
in early pregnancy remains uncertain, 
as these drugs are embryotoxic 
in animals [9,10]. They are not 
recommended for uncomplicated 
malaria in the first trimester, unless 
effective alternatives are unavailable. 
There is now a reasonable body of 
evidence for safety from clinical trials 
in nearly 1,000 women in the second 
and third trimesters of pregnancy, 
and artemisinin-based combination 
treatments are now recommended 
treatments in the second and third 
trimesters [6]. Severe malaria in 
late pregnancy carries a mortality 
approaching 50%—approximately 2.5 
times higher than in non-pregnant 
patients. Artesunate has been shown to 
reduce the mortality of severe malaria 
by 35% compared with quinine, and, 
unlike quinine [11], it does not cause 
severe recurrent hyperinsulinaemic 
hypoglycaemia, for which pregnant 
women are at considerably increased 
risk. But quinine is still the most widely 
used treatment for severe malaria in 
pregnancy. Somehow, the unknown, but 
certainly very small, risk to the foetus 
posed by artesunate is considered to 
exceed the 35% increased risk of both 
mother and baby dying from malaria. 
Although artesunate is clearly now 
the drug of choice in severe malaria, 
there have been no pharmacokinetic 
studies in pregnant women to guide 
dosage. By extrapolation from studies 
in uncomplicated malaria, the currently 
recommended dose could again be too 
low. 
We Need Evidence to Inform 
Practice
What is needed now is evidence. 
Industry is usually reluctant to 
underwrite studies of new drugs in 
pregnant women [2], particularly in 
the tropics. Research centres need to 
be encouraged to study the treatment 
of infections in pregnancy. There is 
now active research on HIV, malaria, 
and helminth infections in pregnancy, 
but not for other tropical infections. 
For antimalarial, antitrypanosomal, 
and antileishmanial drugs, the 
pharmaceutical industry’s role in 
drug development will be increasingly 
assumed by public–private partnerships 
such as the Medicines for Malaria 
Venture and the Drugs for Neglected 
Diseases Initiative. International 
agencies and funders need to provide 
adequate support for quality studies 
in pregnancy and, in an increasingly 
litigious climate, to underwrite the 
liabilities. Pregnancy registries should 
be established to facilitate systematic 
recording of adverse effects on the 
newborn, and assessment of the 
neurological development of infants 
until at least one year of age, and 
preferably longer. 
These are long-term investments. 
Unfortunately, reliable diagnostic 
facilities for malaria, or even birth 
records, are difficult to find in the parts 
of the world where these registries 
need to be established. Particular 
efforts should be made to document 
first-trimester exposures accurately 
to assess teratogenicity risks. This 
documentation could be achieved 
most reliably in specific centres where 
pregnant women attend antenatal 
clinics in the first trimester. 
Research ethics review boards 
have difficult jobs, and tend to err on 
the side of caution (i.e., negativity) 
when confronted with applications to 
study new drugs or drug regimens in 
pregnant women. In assessing the risks 
and benefits, research ethics review 
boards also need to consider the risks 
of our continued ignorance of how 
best to treat serious infectious diseases 
in pregnancy, and the benefits to the 
mother and her baby of appropriate 
treatment. Protagonists always demand 
urgent action, but amongst many 
priorities, optimising the dose of 
existing anti-infective treatments in 
late pregnancy must be near the top. 
Such optimisation means assessing the 
pharmacokinetic properties of systemic 
anti-infective drugs in late pregnancy, 
and where blood concentrations are 
found to be reduced significantly, 
evaluating higher doses. Unfortunately, 
capacity for drug measurement is 
woefully lacking in tropical countries, so 
this too needs to be strengthened [12]. 
Conclusion
“Better safe than sorry” is the mantra 
of our risk-averse age, and there are 
few more challenging areas of drug 
development than establishing drug 
safety in pregnancy. Add to this the 
difficulties in conducting clinical 
trials and pharmacokinetic studies in 
pregnancy in most tropical countries, 
and it is not difficult to understand our 
current state of ignorance. We do not 
know how best to treat most tropical 
infectious diseases in pregnancy. It is a 
difficult problem, but one that should 
no longer be ignored.  
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